Myelofibrosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of myelofibrosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence in each country, as well as annualized case counts projected to the national population.
Clarivate epidemiology’s myelofibrosis forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with myelofibrosis per year?
- Of all people diagnosed with myelofibrosis, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of myelofibrosis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases of myelofibrosis for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulations:
- Diagnosed incident cases of primary and secondary myelofibrosis.
- Diagnosed prevalent cases of primary and secondary myelofibrosis.
- Diagnosed incident cases of primary myelofibrosis by biomarker status and comorbidity.
- Diagnosed incident cases of myelofibrosis by International Prognostic Scoring System.
- Diagnosed prevalent cases of myelofibrosis by Dynamic International Prognostic Scoring System.
- Diagnosed prevalent cases by treatment status.
Note: Coverage may vary by country.
Table of contents
- Myelofibrosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of myelofibrosis)
- Diagnosed incident cases of myelofibrosis
- Diagnosed prevalent cases of myelofibrosis
- Diagnosed incident cases of myelofibrosis by IPSS
- Diagnosed prevalent cases of myelofibrosis by DIPSS
- Diagnosed incident cases of primary myelofibrosis by comorbidity
- Diagnosed prevalent cases of primary myelofibrosis by comorbidity
- Diagnosed incident cases of primary myelofibrosis by biomarker status
- Diagnosed prevalent cases of primary myelofibrosis by biomarker status
- Diagnosed incident cases of secondary myelofibrosis by MYSEC-PM
- Drug-treated prevalent cases of myelofibrosis
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.